As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

12/09/19  Bio-Rad Laboratories, Inc.        8-K:7      12/05/19   11:171K                                   Donnelley … Solutions/FA

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     26K 
 6: R1          Document and Entity Information                     HTML     51K 
 8: XML         IDEA XML File -- Filing Summary                      XML     12K 
10: XML         XBRL Instance -- d803533d8k_htm                      XML     17K 
11: EXCEL       IDEA Workbook of Financial Reports                  XLSX      6K 
 3: EX-101.DEF  XBRL Definitions -- bio-20191205_def                 XML     40K 
 4: EX-101.LAB  XBRL Labels -- bio-20191205_lab                      XML     65K 
 5: EX-101.PRE  XBRL Presentations -- bio-20191205_pre               XML     41K 
 2: EX-101.SCH  XBRL Schema -- bio-20191205                          XSD     15K 
 7: JSON        XBRL Instance as JSON Data -- MetaLinks               14±    21K 
 9: ZIP         XBRL Zipped Folder -- 0001193125-19-308499-xbrl      Zip     10K 

 i false  i 0000012208 0000012208 2019-12-05 2019-12-05 0000012208 us-gaap:CommonStockMember 2019-12-05 2019-12-05 0000012208 us-gaap:CommonClassBMember 2019-12-05 2019-12-05

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM  i 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report:  i December 5, 2019

(Date of earliest event reported)

 i BIO-RAD LABORATORIES, INC.

(Exact name of registrant as specified in its charter)

Commission File Number:  i 1-7928

i Delaware		i 94-1381833
(State or other jurisdiction of incorporation)		(I.R.S. Employer Identification No.)

 i 1000 Alfred Nobel Dr.

 i Hercules,  i California  i 94547

(Address of principal executive offices, including zip code)

 i (510)  i 724-7000

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

i ☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

i ☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

i ☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

i ☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
i Class A Common Stock, Par Value $0.0001 per share		i BIO		i New York Stock Exchange
i Class B Common Stock, Par Value $0.0001 per share		i BIOb		i New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company   i ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

ITEM 7.01

Regulation FD Disclosure

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) (“Bio-Rad”) today announced that on the evening of December 5, 2019, Bio-Rad detected a ransomware attack on its network. Bio-Rad immediately took certain systems offline as part of its comprehensive response to contain the activity. Work is ongoing to restore full system functionality as quickly as possible. Customers may experience delays in placing orders while Bio-Rad’s systems are down. At this time, there is no evidence of unauthorized transfer or misuse of data.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				BIO-RAD LABORATORIES, INC.
Date: December 6, 2019				By:		/s/ Timothy S. Ernst
						Timothy S. Ernst
						EVP, General Counsel and Secretary